Proteomic study reveals downregulation of apolipoprotein A1 in plasma of poorly controlled diabetes: A pilot study

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 495-498

  Bhonsle, Hemangi S ^a   Korwar, Arvind M ^a   Chougale, Ashok D ^a   Kote, Sachin S ^a   Dhande, Nitin L ^b   Shelgikar, Kishore M ^b   Kulkarni, Mahesh J ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

^b Maharashtra Medical Research Society (MMRS)   (India)

Author keywords

Biomarker; HbA1c; Proteomics

Indexed keywords

ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; FIBRINOGEN; GLYCOSYLATED HEMOGLOBIN; HAPTOGLOBIN; PREALBUMIN; VITAMIN D BINDING PROTEIN;

ARTICLE; CONTROLLED DIABETES MELLITUS; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PILOT STUDY; POORLY CONTROLLED DIABETES MELLITUS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

APOLIPOPROTEIN A-I; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS; DOWN-REGULATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MASS SPECTROMETRY; PILOT PROJECTS; PROTEOME;

EID: 84873865761     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1223     Document Type: Article

References (28)

1. Anderson NL and Anderson NG: The human plasma proteome: history, character and diagnostic prospects. Mol Cell Proteomics 1: 845-867, 2002.
2. Anderson NL: The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 56: 177-185, 2010.
3. Taylor R and Agius L: The biochemistry of diabetes. Biochem J 250: 625-640, 1988.
4. Chase HP, Jackson WE, Hoops SL, et al: Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 261: 1155-1160, 1989.
5. Takahashi S, Uchino H, Shimizu T, et al: Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J 54: 139-144, 2007.
6. Sundsten T and Ortsater H: Proteomics in diabetes research. Mol Cell Endocrinol 297: 93-103, 2009.
7. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
8. Giacco F and Brownlee M: Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010.
9. Bousova I, Bakala H, Chudacek R, et al: Glycation-induced inactivation of aspartate aminotransferase, effect of uric acid. Mol Cell Biochem 278: 85-92, 2005.
10. Hashemi M, Naderi M, Rashidi H, et al: Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res Clin Pract 75: 246-248, 2007.
11. Mohammad TG, Mojtaba R and Mohsen R: Study of nonenzymatic glycation of transferrin and its effect on iron-binding antioxidant capacity. Iran J Basic Med Sci 13: 194-199, 2010.
12. Jung T and Grune T: The proteasome and its role in the degradation of oxidized proteins. IUBMB Life 11: 743-752, 2008.
13. Winter WE and Schatz DA: Autoimmune markers in diabetes. Clin Chem 57: 168-175, 2011.
14. Tessari P, Kiwanuka E, Millioni R, et al: Albumin and fibrinogen synthesis and insulin effect in type 2 diabetic patients with normoalbuminuria. Diabetes Care 29: 323-328, 2006.
15. Peavy DE, Taylor JM and Jefferson LS: Correlation of albumin production rates and albumin mRNA levels in livers of normal, diabetic and insulin-treated diabetic rats. Proc Natl Acad Sci USA 75: 5879-5883, 1978.
16. Blanton D, Han Z, Bierschenk L, et al: Reduced serum vitamin D-binding protein levels are associated with type 1 diabetes. Diabetes 60: 2566-2570, 2011.
17. Ceriello A: Fibrinogen and diabetes mellitus: is it time for intervention trials? Diabetologia 40: 731-734, 1997.
18. Engstrom G, Hedblad B, Eriksson KF, et al: Complement C3 is a risk factor for the development of diabetes. A population-based cohort study. Diabetes 54: 570-575, 2005.
19. Lapolla A, Brioschi M, Banfi C, et al: On the search for glycated lipoprotein Apo A-I in the plasma of diabetic and nephropathic patients. J Mass Spectrom 43: 74-81, 2008.
20. Cheng FY, Blackburn K, Lin YM, et al: Absolute protein quantification by LC/MS(E) for global analysis of salicylic acid-induced plant protein secretion responses. J Proteome Res 8: 82-93, 2009.
21. Quintao EC, Medina WL, Passarelli M: Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 16: 237-250, 2000.
22. Vuilleumier N, Bas S, Pagano S, et al: Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 62: 2640-2650, 2010.
23. Montecucco F, Vuilleumier N, Pagano S, et al: Anti-Apolipo-protein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 32: 412-421, 2011.
24. Haas MJ, Horani M, Mreyoud A, et al: Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. Biochim Biophys Acta 1623: 120-128, 2003.
25. Mooradian AD, Haas MJ and Wong NC: Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes 53: 513-520, 2004.
26. Mallick KA, Joshi MR and Bhat PG: A study on Apo B100/Apo A-I ratio in uncontrolled type 2 diabetes mellitus. Int J Appl Biol Pharm Technol 2: 379-384, 2011.
27. Wagner AM and Ordonez-Llanos J: Apolipoproteins and prediction of fatal myocardial infarction. Lancet 359: 1863-1864, 2002.
28. Zoppini G, Targher G, Chonchol M, et al: Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 19: 580-586, 2009.